Orlistat induces ferroptosis-like cell death of lung cancer cells
Wenjing Zhou1, Jing Zhang3, Mingkun Yan4, Jin Wu1, Shuo Lian4, Kang Sun1, Baiqing Li5, Jia Ma2, Jun Xia2(), Chaoqun Lian2()
1. Research Center of Clinical Laboratory Science, Bengbu Medical College, Bengbu 233030, China 2. Department of Biochemistry and Molecular Biology, School of Laboratory Medicine, Bengbu Medical College, Bengbu 233030, China 3. Department of Genetics, School of Life Sciences, Bengbu Medical College, Bengbu 233000, China 4. Department of Clinical Medicine, Bengbu Medical College, Bengbu 233000, China 5. Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu 233030, China
Aberrant de novo lipid synthesis is involved in the progression and treatment resistance of many types of cancers, including lung cancer; however, targeting the lipogenetic pathways for cancer therapy remains an unmet clinical need. In this study, we tested the anticancer activity of orlistat, an FDA-approved anti-obesity drug, in human and mouse cancer cells in vitro and in vivo, and we found that orlistat, as a single agent, inhibited the proliferation and viabilities of lung cancer cells and induced ferroptosis-like cell death in vitro. Mechanistically, we found that orlistat reduced the expression of GPX4, a central ferroptosis regulator, and induced lipid peroxidation. In addition, we systemically analyzed the genome-wide gene expression changes affected by orlistat treatment using RNA-seq and identified FAF2, a molecule regulating the lipid droplet homeostasis, as a novel target of orlistat. Moreover, in a mouse xenograft model, orlistat significantly inhibited tumor growth and reduced the tumor volumes compared with vehicle control (P<0.05). Our study showed a novel mechanism of the anticancer activity of orlistat and provided the rationale for repurposing this drug for the treatment of lung cancer and other types of cancer.
F Bray, J Ferlay, I Soerjomataram, RL Siegel, LA Torre, A Jemal. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394–424 https://doi.org/10.3322/caac.21492
pmid: 30207593
2
AM Gouw, LS Eberlin, K Margulis, DK Sullivan, GG Toal, L Tong, RN Zare, DW Felsher. Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. Proc Natl Acad Sci USA 2017; 114(17): 4300–4305 https://doi.org/10.1073/pnas.1617709114
pmid: 28400509
3
C Lu, J Ma, D Cai. Increased HAGLR expression promotes non-small cell lung cancer proliferation and invasion via enhanced de novo lipogenesis. Tumour Biol 2017; 39(4): 1010428317697574 https://doi.org/10.1177/1010428317697574
pmid: 28443464
4
A Singh, C Ruiz, K Bhalla, JA Haley, QK Li, G Acquaah-Mensah, E Montal, KR Sudini, F Skoulidis, II Wistuba II, V Papadimitrakopoulou, JV Heymach, LG Boros, E Gabrielson, J Carretero, KK Wong, JD Haley, S Biswal, GD Girnun. De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer. FASEB J 2018; 32(12): 7018−7027 https://doi.org/10.1096/fj.201800204
pmid: 29906244
5
A Ali, E Levantini, JT Teo, J Goggi, JG Clohessy, CS Wu, L Chen, H Yang, I Krishnan, O Kocher, J Zhang, RA Soo, K Bhakoo, TM Chin, DG Tenen. Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer. EMBO Mol Med 2018; 10(3): e8313 https://doi.org/10.15252/emmm.201708313
pmid: 29449326
ML Drent, I Larsson, T William-Olsson, F Quaade, F Czubayko, K von Bergmann, W Strobel, L Sjöström, EA van der Veen. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord 1995; 19(4): 221–226
pmid: 7627244
A Schcolnik-Cabrera, A Chávez-Blanco, G Domínguez-Gómez , L Taja-Chayeb, R Morales-Barcenas, C Trejo-Becerril, E Perez-Cardenas, A Gonzalez-Fierro, A Dueñas-González. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy. Expert Opin Investig Drugs 2018; 27(5): 475–489 https://doi.org/10.1080/13543784.2018.1471132
pmid: 29723075
10
E Sokolowska, M Presler, E Goyke, R Milczarek, J Swierczynski, T Sledzinski. Orlistat reduces proliferation and enhances apoptosis in human pancreatic cancer cells (PANC-1). Anticancer Res 2017; 37(11): 6321–6327
pmid: 29061815
A Czumaj, J Zabielska, A Pakiet, A Mika, O Rostkowska, W Makarewicz, J Kobiela, T Sledzinski, E Stelmanska. In vivo effectiveness of orlistat in the suppression of human colorectal cancer cell proliferation. Anticancer Res 2019; 39(7): 3815–3822 https://doi.org/10.21873/anticanres.13531
pmid: 31262909
13
BJ You, LY Chen, PH Hsu, PH Sung, YC Hung, HZ Lee. Orlistat displays antitumor activity and enhances the efficacy of paclitaxel in human hepatoma Hep3B cells. Chem Res Toxicol 2019; 32(2): 255–264 https://doi.org/10.1021/acs.chemrestox.8b00269
pmid: 30667213
14
LY de Almeida, FS Mariano, DC Bastos, KA Cavassani, J Raphelson, VS Mariano, M Agostini, FS Moreira, RD Coletta, RO Mattos-Graner, E Graner. The antimetastatic activity of orlistat is accompanied by an antitumoral immune response in mouse melanoma. Cancer Chemother Pharmacol 2020; 85(2): 321–330 https://doi.org/10.1007/s00280-019-04010-1
pmid: 31863126
15
C Zhang, L Sheng, M Yuan, J Hu, Y Meng, Y Wu, L Chen, H Yu, S Li, G Zheng, Z Qiu. Orlistat delays hepatocarcinogenesis in mice with hepatic co-activation of AKT and c-Met. Toxicol Appl Pharmacol 2020; 392: 114918 https://doi.org/10.1016/j.taap.2020.114918
pmid: 32045588
16
G Cioccoloni, A Aquino, M Notarnicola, MG Caruso, E Bonmassar, M Zonfrillo, S Caporali, I Faraoni, C Villivà, MP Fuggetta, O Franzese. Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line. J Chemother 2020; 32(1): 30–40 https://doi.org/10.1080/1120009X.2019.1694761
pmid: 31775585
17
GP Drummen, LC van Liebergen, JA Op den Kamp, JA Post. C11-BODIPY(581/591), an oxidation-sensitive fluorescent lipid peroxidation probe: (micro)spectroscopic characterization and validation of methodology. Free Radic Biol Med 2002; 33(4): 473–490 https://doi.org/10.1016/S0891-5849(02)00848-1
pmid: 12160930
18
TS Angeles, RL Hudkins. Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors. Expert Opin Drug Discov 2016; 11(12): 1187–1199 https://doi.org/10.1080/17460441.2016.1245286
pmid: 27701891
19
D Calderón Guzmán, E Hernández García, A Juárez Jacobo, L Segura Abarca, G Barragán Mejía, R Rodríguez Pérez , H Juárez Olguín. Effect of orlistat on lipid peroxidation, Na+, K+ ATPase, glutathione and serotonin in rat brain. Proc West Pharmacol Soc 2011; 54: 73–77
pmid: 22423586
20
H Imai, M Matsuoka, T Kumagai, T Sakamoto, T Koumura. Lipid peroxidation-dependent cell death regulated by GPx4 and ferroptosis. Curr Top Microbiol Immunol 2017; 403: 143–170 https://doi.org/10.1007/82_2016_508
pmid: 28204974
21
WS Yang, R SriRamaratnam, ME Welsch, K Shimada, R Skouta, VS Viswanathan, JH Cheah, PA Clemons, AF Shamji, CB Clish, LM Brown, AW Girotti, VW Cornish, SL Schreiber, BR Stockwell. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014; 156(1-2): 317–331 https://doi.org/10.1016/j.cell.2013.12.010
pmid: 24439385
22
J Wu, AM Minikes, M Gao, H Bian, Y Li, BR Stockwell, ZN Chen, X Jiang. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature 2019; 572(7769): 402–406 https://doi.org/10.1038/s41586-019-1426-6
pmid: 31341276
23
I Poursaitidis, X Wang, T Crighton, C Labuschagne, D Mason, SL Cramer, K Triplett, R Roy, OE Pardo, MJ Seckl, SW Rowlinson, E Stone, RF Lamb. Oncogene-selective sensitivity to synchronous cell death following modulation of the amino acid nutrient cystine. Cell Rep 2017; 18(11): 2547–2556 https://doi.org/10.1016/j.celrep.2017.02.054
pmid: 28297659
24
Y Li, X Yang, J Yang, H Wang, W Wei. An 11-gene-based prognostic signature for uveal melanoma metastasis based on gene expression and DNA methylation profile. J Cell Biochem 2019; 120: 8630–8639 https://doi.org/10.1002/jcb.28151
pmid: 30556166